Lisinopril Tablets, USP, for oral administration, are available as
Pink, oval, biconvex, uncoated tablets debossed “E 54” on one side and bisected on the other side and supplied as:
NDC 0185-5400-01 bottles of 100
NDC 0185-5400-10 bottles of 1000
NDC 69189-5400-1 single dose pack with 1 tablet as repackaged by Avera McKennan Hospital
Store at 20º to 25ºC (68º to 77ºF) [see USP Controlled Room Temperature]. Protect from moisture, freezing and excessive heat. Dispense in a tight container.
This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.
Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to notify their healthcare provider with a known or suspected pregnancy [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)].
Angioedema, including laryngeal edema may occur at any time during treatment with angiotensin converting enzyme inhibitors, including lisinopril. Tell patients to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician.
Advise women not to breastfeed during treatment with lisinopril [see Use in Specific Populations (8.2)].
Tell patients to report light-headedness especially during the first few days of therapy. If actual syncope occurs, tell the patient to discontinue the drug until they have consulted with the prescribing physician.
Tell patients that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; advise patients accordingly.
Tell patients not to use salt substitutes containing potassium without consulting their physician.
Tell diabetic patients treated with oral antidiabetic agents or insulin starting an ACE inhibitor to monitor for hypoglycaemia closely, especially during the first month of combined use [see Drug Interactions (7.2)].
Tell patients to report promptly any indication of infection (e.g., sore throat, fever), which may be a sign of leukopenia/neutropenia.
Princeton, NJ 08540
Rev. May 2016
| LISINOPRIL |
|Labeler — Avera McKennan Hospital (068647668)|
|Avera McKennan Hospital||068647668||relabel (69189-5400), repack (69189-5400)|
Revised: 03/2017 Avera McKennan Hospital
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.